Clinical Trials Arena on MSN1d
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success
The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
Researchers develop method to identify dormant cells that carry HIV
Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...
Healio3d
Two more people potentially cured of HIV
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
“Magic” for Those Who Can’t Take Pills: Groundbreaking HIV Treatment Achieves 98% Viral Suppression
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
Managed Healthcare Executive23h
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
The American Journal of Managed Care3d
Self-Testing in HIV Shows Promise in Early Studies
Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...
University of California, San Francisco3d
Injectable Therapy Is ‘Magic’ for Those Who Can’t Take HIV Pills
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...
Fierce Biotech3d
Immunocore T-cell engager clears safety hurdle, reduces HIV reservoir in some patients
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
AUDIO: HIV cases explode in Fiji
Follow the latest news headlines from Australia's most trusted source. Read in-depth expert analysis and watch live coverage on ABC News.